公开(公告)号：US20210309702A1

公开(公告)日：2021-10-07

申请号：US17164624

申请日：2021-02-01

申请人： The Regents of the University of Colorado, a body corporate

发明人： Xuedong Liu ,  Xiaojuan Zhang ,  Zeyu Liu ,  Quanbin Xu

IPC分类号： C07K14/005 ,  A61K9/51 ,  C12N7/00 ,  C12N15/11 ,  C12N9/22 ,  A61K38/46 ,  A61K31/7088

摘要： The invention includes systems, methods, and compositions for designing secreted fusogenic ectosome vesicles, or gectosomes, that selectively encapsulate specific target proteins, nucleic acids and/or other small molecules in a predetermined manner. These engineered gectosomes can be used to deliver desired cargos to receipt cells in vitro, ex vivo, or in vivo and may further reprogram target cellular phenotypes in a dose-dependent manner, as well as perform genome editing functions, among others.

公开(公告)号：US20210244686A1

公开(公告)日：2021-08-12

申请号：US17255214

申请日：2019-06-24

申请人： The Regents of the University of Colorado a body corporate

发明人： Xuedong Liu ,  Douglas Chapnick ,  William Old

IPC分类号： A61K31/05 ,  A61K31/352 ,  A61K31/192 ,  A61K31/09 ,  A61K45/06 ,  A61K31/445 ,  A61K31/13 ,  A61K31/27 ,  A61K31/55 ,  A61P3/06

摘要： The invention includes the use of cannabidiol (CBD), and cannabidiol analogs, as therapeutic compounds or formulations for the increase of lipid order in the cell membranes of a patient. This increase in membrane lipid order may cause downstream therapeutic effects that may ameliorate certain disease conditions such as cardio vascular disease, high-cholesterol and Alzheimer's disease.

公开(公告)号：USRE47690E1

公开(公告)日：2019-11-05

申请号：US15968188

申请日：2018-05-01

申请人： The Regents of the University of Colorado, A Body Corporate

发明人： Xuedong Liu ,  Gan Zhang ,  Daniel Chuen-Fong Chan ,  Anthony D. Piscopio

IPC分类号： C07D513/04 ,  C07D473/16 ,  C07D473/34 ,  C07D487/04

摘要： The present invention relates to novel hydroxamic acids which are specific histone deacetylase (HDAC) inhibitors and/or TTK/Mps1 kinase inhibitors, including pharmaceutically acceptable salts thereof, which are useful for modulating HDAC and/or TTK/Mps1 kinase activity, pharmaceutical compositions comprising these compounds, and processes for their preparation.

公开(公告)号：US20180306800A1

公开(公告)日：2018-10-25

申请号：US15959158

申请日：2018-04-20

申请人： The Regents of the University of Colorado, a body corporate

发明人： Xuedong Liu ,  Gail Eckhardt ,  Gan Zhang ,  Conggang Zhang ,  Zeyu Liu ,  Eric Bunker

IPC分类号： G01N33/574 ,  A61P35/00 ,  A61K31/44 ,  A61K31/495 ,  A61K31/704 ,  A61K39/395 ,  A61K38/15 ,  A61K31/277 ,  C12Q1/6886

CPC分类号： G01N33/57492 ,  A61K31/277 ,  A61K31/44 ,  A61K31/495 ,  A61K31/704 ,  A61K38/15 ,  A61K39/39558 ,  A61P35/00 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/158

摘要： Methods and materials involved in assessing samples (e.g., cancer cells) for the status of PINK1-Parkin pathway biomarkers, as well as materials and methods for identifying cancer patients likely to respond to a particular cancer treatment regimen.

公开(公告)号：US20180044352A1

公开(公告)日：2018-02-15

申请号：US15654662

申请日：2017-07-19

申请人： The Regents of the University of Colorado, A Body Corporate

发明人： Xuedong Liu ,  Gan Zhang ,  Daniel Chuen-Fong Chan ,  Anthony D. Piscopio

IPC分类号： C07D513/04 ,  C07D487/04 ,  C07D473/16 ,  C07D473/34

摘要： The present invention relates to novel hydroxamic acids which are specific histone deacetylase (HDAC) inhibitors and/or TTK/Mps1 kinase inhibitors, including pharmaceutically acceptable salts thereof, which are useful for modulating HDAC and/or TTK/Mps1 kinase activity, pharmaceutical compositions comprising these compounds, and processes for their preparation.

公开(公告)号：US20170081343A1

公开(公告)日：2017-03-23

申请号：US15310743

申请日：2015-05-14

申请人： The Regents of the University of Colorado, A Body Corporate

发明人： Xuedong Liu ,  Gan Zhang ,  Daniel Chuen-Fong Chan ,  Anthony D. Piscopio

IPC分类号： C07D513/04 ,  C07D487/04 ,  C07D473/16

CPC分类号： C07D513/04 ,  C07D473/16 ,  C07D473/34 ,  C07D487/04

摘要： The present invention relates to novel hydroxamic acids which are specific histone deacetylase (HDAC) inhibitors and/or TTK/Mps1 kinase inhibitors, including pharmaceutically acceptable salts thereof, which are useful for modulating HDAC and/or TTK/Mps1 kinase activity, pharmaceutical compositions comprising these compounds, and processes for their preparation.

公开(公告)号：US20150010541A1

公开(公告)日：2015-01-08

申请号：US14289877

申请日：2014-05-29

申请人： The Regents of the University of Colorado, A Body Corporate

发明人： Xuedong Liu ,  Andrew J. Phillips ,  Dana Ungermannova ,  Christopher G. Nasveschuk ,  Gan Zhang

IPC分类号： C07K11/02 ,  A61K45/06 ,  A61K38/15

CPC分类号： C07K11/02 ,  A61K31/425 ,  A61K38/005 ,  A61K38/15 ,  A61K39/3955 ,  A61K45/06 ,  C07K5/0821 ,  C07K11/00

摘要： The present invention provides a novel macrocyclic compound of general Formula (I) having histone deacetylase (HDAC) inhibitory activity, a pharmaceutical composition comprising the compound, and a method useful to treat diseases using the compound.

摘要翻译： 本发明提供了具有组蛋白脱乙酰酶（HDAC）抑制活性的通式（I）的新型大环化合物，包含该化合物的药物组合物和可用于使用该化合物治疗疾病的方法。

公开(公告)号：US20240102991A1

公开(公告)日：2024-03-28

申请号：US18386764

申请日：2023-11-03

申请人： The Regents of the University of Colorado, a body corporate

发明人： Xuedong Liu ,  Douglas A. Chapnick ,  William Old ,  Tristan D. Mcclure-Begley ,  Eric Bunker

IPC分类号： G01N33/50 ,  C12M1/34 ,  C12Q1/6825 ,  G01N21/64 ,  G01N33/542 ,  G01N33/554 ,  G01N33/58

CPC分类号： G01N33/5008 ,  C12M1/3476 ,  C12Q1/6825 ,  G01N21/64 ,  G01N21/6428 ,  G01N21/6452 ,  G01N33/542 ,  G01N33/554 ,  G01N33/582 ,  B01L2300/0636 ,  C12Q2500/00 ,  C12Q2560/00 ,  C12Q2563/107 ,  C12Q2563/179 ,  C12Q2565/1015 ,  C12Q2600/136 ,  G01N2500/04 ,  G01N2800/52

摘要： Provided are FRET-based biosensor constructs, and multiplexed platforms or arrays of these biosensor constructs useful for screening candidate drug molecules for efficacy and/or specificity of drug activity. Optionally the biosensor constructs may be located on an inner membrane within a cell or engineered to be located on the cell's surface. The cells or cell lines displaying the biosensors on a cell surface may be arranged as an array of cells for high throughput evaluation of the efficacy and/or specificity of drug candidates, such as a library of candidate drug compounds.

公开(公告)号：US20210181181A1

公开(公告)日：2021-06-17

申请号：US16954100

申请日：2018-12-14

申请人： The Regents of the University of Colorado, a body corporate

发明人： Xuedong Liu ,  Douglas A. Chapnick ,  William Old ,  Tristan D. Mcclure-Begley ,  Eric Bunker

IPC分类号： G01N33/50 ,  G01N21/64

摘要： Provided are FRET-based biosensor constructs, and multiplexed platforms or arrays of these biosensor constructs useful for screening candidate drug molecules for efficacy and/or specificity of drug activity. Optionally the biosensor constructs may be located on an inner membrane within a cell or engineered to be located on the cell's surface. The cells or cell lines displaying the biosensors on a cell surface may be arranged as an array of cells for high throughput evaluation of the efficacy and/or specificity of drug candidates, such as a library of candidate drug compounds.

公开(公告)号：US10508122B2

公开(公告)日：2019-12-17

申请号：US15654662

申请日：2017-07-19

申请人： The Regents of the University of Colorado, A Body Corporate

发明人： Xuedong Liu ,  Gan Zhang ,  Daniel Chuen-Fong Chan ,  Anthony D. Piscopio

IPC分类号： C07D513/04 ,  C07D473/34 ,  C07D487/04 ,  C07D473/16

摘要： The present invention relates to novel hydroxamic acids which are specific histone deacetylase (HDAC) inhibitors and/or TTK/Mps1 kinase inhibitors, including pharmaceutically acceptable salts thereof, which are useful for modulating HDAC and/or TTK/Mps1 kinase activity, pharmaceutical compositions comprising these compounds, and processes for their preparation.